CJC-1295 (Modified GRF 1-29, no DAC) Research Vial 5mg

CJC-1295 (Modified GRF 1-29, no DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH). It corresponds to the first 29 amino acids of endogenous GHRH with structural modifications that enhance stability and receptor-binding affinity. The “no DAC” variant lacks the Drug Affinity Complex (DAC) moiety, resulting in a shorter half-life of approximately 30 minutes and preservation of the natural pulsatile pattern of GH secretion—a key distinction from the DAC-conjugated form. The mechanism of action involves selective activation of GHRH receptors on somatotropic cells of the anterior pituitary gland. This stimulation triggers the synthesis and pulsatile release of growth hormone, which in turn elevates circulating insulin-like growth factor 1 (IGF-1) levels. The resulting anabolic signaling cascade supports research models of muscle protein synthesis, bone density modulation, and metabolic regulation. CJC-1295 without DAC is frequently combined with ghrelin mimetics such as Ipamorelin in research protocols, as the two compounds act synergistically on GH release through complementary pathways (GHRH receptor agonism and ghrelin receptor agonism, respectively). The peptide has reached Phase 2 clinical trials and is categorized under Growth Hormone / IGF-1 Axis research. AllDayGLP supplies CJC-1295 (Modified GRF 1-29, no DAC) as a lyophilized powder (5 mg per vial) with ≥98% purity verified by HPLC analysis. Each batch is third-party tested with a Certificate of Analysis provided. This product is intended for laboratory research purposes only and is not for human or veterinary use.